Loading clinical trials...
Loading clinical trials...
The purpose of this study is to determine the safety and tolerability of NGM313, both single dose and multiple doses, in normal healthy overweight and obese adult participants.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
NGM Biopharmaceuticals, Inc
NCT06894498 · Obesity and Obesity-related Medical Conditions, Weight Loss
NCT05124808 · Gestational Diabetes, Pregnancy, High Risk, and more
NCT07595549 · Obesity, Overweight and/or Obesity, and more
NCT06937086 · Ulcerative Colitis, Obesity or Overweight
NCT07284875 · Obesity, Overweight
NGM Clinical Study Site
Melbourne, Victoria
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions